Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study.

TitleCombined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study.
Publication TypeJournal Article
Year of Publication2000
AuthorsKlijn JG, Beex LV, Mauriac L, van Zijl JA, Veyret C, Wildiers J, Jassem J, Piccart M, Burghouts J, Becquart D, Seynaeve C, Mignolet F, Duchateau L
JournalJournal of the National Cancer Institute
Volume92
Issue11
Pagination903-11
Date Published2000 Jun 7
Abstract

Surgical or medical castration and antiestrogenic treatment with tamoxifen are common endocrine treatments for premenopausal women with breast cancer. However, tamoxifen therapy induces high levels of plasma estradiol, with unknown long-term effects. In this study, we investigated the effect of combining estrogen suppression with the luteinizing hormone-releasing hormone agonist buserelin and estradiol receptor blockade with tamoxifen to determine whether the high estradiol levels induced by tamoxifen could be reduced and whether the antitumor effects would be better.

Alternate JournalJ. Natl. Cancer Inst.